stockrow
Friday 6 November 2026
Export NXGL’s income statement to Excel — free account
NexGel, Inc.
NXGL Healthcare Medical Instruments & Supplies
NexGel, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.4 million, up 31.5% from fiscal 2024.
- Revenue
- +27.8%
- EPS
- −344.4%
- Free cash flow
- −432.3%
- Total debt
- +353.8%
Quarter to June 2026, against a year earlier
3.60
0.52
−12.62%
Follow NXGL
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.37 | 0.46 | 1.11 | 1.67 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(2.06) | (10.30) | 45.00 | (24.78) | |
P/B ratio |
0.83 | 1.16 | 2.59 | 3.49 | |
Price to Tangible BV |
0.00 | 1.92 | 4.10 | 5.21 | |
EV/Sales |
0.55 | 0.46 | 1.09 | 1.58 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(2.06) | (3.65) | (9.46) | (7.53) | |
EV/FCF |
(1.97) | (3.46) | (8.57) | (7.21) | |
Quick Ratio |
0.19 | 0.84 | 0.59 | 0.82 | |
Current Ratio |
0.43 | 1.70 | 1.47 | 1.69 | |
Net Debt/EBITDA |
5.23 | 0.16 | 0.40 | 1.49 | |
Debt/Assets |
13.97% | 17.25% | 6.99% | 6.66% | |
Debt/Equity |
0.68 | 0.45 | 0.15 | 0.14 | |
Asset Turnover |
0.67 | 1.02 | 1.07 | 1.05 | |
Operating CF/Net income |
0.60 | 0.54 | (0.29) | 1.20 | |
Capex/Depreciation |
(0.03) | (0.05) | (0.10) | 2.67 | |
Interest Coverage |
— | (22.81) | (52.78) | 72.50 | |
Research and Development Expense of Revenue |
0.54% | 0.00% | (0.21%) | 0.24% | |
Selling, General and Administrative Expense of Revenue |
97.50% | 76.19% | 72.94% | 66.84% | |
Intangible Assets out of Total Assets |
0.55 | 0.15 | 0.17 | 0.16 | |
Share Based Compensation of Revenue |
3.23% | 5.40% | 5.58% | 6.99% | |
Graham Net Nets |
(3.28) | (0.28) | (0.10) | (0.02) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(141.72%) | (63.19%) | (23.60%) | (15.16%) | |
Free Cash Flow Yield |
(73.91%) | (28.73%) | (11.45%) | (13.17%) | |
Revenue per Share |
8.18 | 6.46 | 7.12 | 7.36 | |
Operating CF per Share |
(4.87) | (1.23) | 0.72 | (1.97) | |
Capex per Share |
(0.17) | (0.02) | (0.10) | (0.02) | |
Free Cash Flow per Share |
(5.04) | (1.25) | 0.61 | (1.99) | |
Cash per Share |
3.79 | 5.17 | 2.69 | 4.66 | |
Shareholders Equity per Share |
12.13 | 10.93 | 12.45 | 13.99 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
12.13 | 10.93 | 12.45 | 13.99 | |
Free Cash Flow |
(2.27) | (0.51) | 0.24 | (0.79) | |
Working Capital |
(8.27) | 2.32 | 1.38 | 2.29 | |
Capital Expenditures |
(0.08) | (0.01) | (0.04) | (0.01) | |
Net Current Asset Value |
(14.81) | (1.48) | (1.23) | (0.44) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.00 | 0.01 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.92 | 0.79 | 0.80 | 0.87 | |
Average Payables |
2.60 | 1.64 | 1.29 | 1.36 | |
Average Inventory |
2.06 | 2.05 | 1.93 | 1.90 | |
Average Assets |
18.08 | 11.02 | 10.72 | 11.10 | |
Average Common Equity |
5.26 | 5.03 | 5.49 | 5.28 |
Columns are period end dates · fundamentals updated 2 Nov 2026